Author/Authors :
Azizi، Gholamreza نويسنده Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran. Azizi, Gholamreza , Rastegar Pouyani، Mohsen نويسنده Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Rastegar Pouyani, Mohsen , Navabi، Shadi Sadat نويسنده Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Navabi, Shadi Sadat , Yazdani، Reza نويسنده Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ; Research Center for Immunodeficiencies, Childrens Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Yazdani, Reza , Kiaee، Fatemeh نويسنده MA Graduate , , Mirshafiey، Abbas نويسنده ,
Abstract :
Leukemia is a hematological tumor in which the malignant myeloid or lymphoid subsets play a pivotal role. Newly identified T helper cell 22 (Th22) is a subset of CD4(+) T cells with distinguished gene expression, function and specific properties apart from other known CD4(+) T cell subsets.Th22 cells are characterized by production of a distinct profile of effector cytokines, including interleukin (IL)-22, IL-13, and tumor necrosis factor-α (TNF-α). The levels of Th22 and cytokine IL-22 are increased and positively related to inflammatory and autoimmune disorders. Recently, several studies have reported the changes in frequency and function of Th22 in acute leukemic disorders as AML and ALL. This review discusses the role of Th22 and its cytokine IL-22 in the immunopathogenesis of leukemic disease.
